Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.

@article{Neuvonen2010DrugIW,
  title={Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.},
  author={Pertti J Neuvonen},
  journal={Current opinion in investigational drugs},
  year={2010},
  volume={11 3},
  pages={323-32}
}
HMG-CoA reductase inhibitors (statins) can cause skeletal muscle toxicity; the risk of toxicity is elevated by drug interactions and pharmacogenetic factors that increase the concentration of statins in the plasma. Statins are substrates for several membrane transporters that may mediate drug interactions. Inhibitors of the organic anion transporting polypeptide 1B1 can decrease the hepatic uptake of many statins, as well as the therapeutic index of these agents. Potent inhibitors of cytochrome… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum.

Proceedings of the National Academy of Sciences of the United States of America • 2015
View 9 Excerpts
Highly Influenced

Chromatin Regulation of Early Embryonic Lineage Specification

Advances in Anatomy, Embryology and Cell Biology • 2018
View 1 Excerpt

Pitavastatin: A Review in Hypercholesterolemia.

American journal of cardiovascular drugs : drugs, devices, and other interventions • 2017
View 1 Excerpt

Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.

Antimicrobial agents and chemotherapy • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…